Curanex Pharmaceuticals Inc Common Stock Working Capital to Net Assets Ratio

Latest as of September 2025: 99.6%

Curanex Pharmaceuticals Inc Common Stock working capital to net assets ratio. Curanex Pharmaceuticals Inc Common Stock (CURX) has a Working Capital to Net Assets ratio of 99.6% as of September 2025. Working capital of $14.23 Million (current assets of $14.42 Million minus current liabilities of $185.96K) is measured against net assets of $14.29 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Curanex Pharmaceuticals Inc Common Stock (CURX) tangible equity ratio to evaluate the tangible quality of the company's equity base.

WC/NA Ratio

99.6%
Working Capital / Net Assets

Working Capital

$14.23 Million
USD

Current Assets

$14.42 Million
USD

Current Liabilities

$185.96K
USD

Working Capital to Net Assets Ratio of Curanex Pharmaceuticals Inc Common Stock (2022–2024)

Working capital to net assets ratio of Curanex Pharmaceuticals Inc Common Stock from 2022 to 2024. This chart shows how Curanex Pharmaceuticals Inc Common Stock's Working Capital to Net Assets ratio has evolved across 3 annual periods from 2022 to 2024. As of September 2025, the ratio stands at 99.6%, reflecting working capital of $14.23 Million against net assets of $14.29 Million USD. Read how much debt does Curanex Pharmaceuticals Inc Common Stock carry for a breakdown of total debt and financial obligations.

Curanex Pharmaceuticals Inc Common Stock Working Capital to Net Assets Ratio by Year (2022–2024)

Curanex Pharmaceuticals Inc Common Stock working capital to net assets ratio by year from 2022 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Curanex Pharmaceuticals Inc Common Stock from 2022 to 2024, covering 3 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see how large is Curanex Pharmaceuticals Inc Common Stock's balance sheet.

Year WC/NA Ratio Working Capital (USD) Net Assets Current Assets Current Liabilities Change (pp)
2024 100.0% $503.36K $503.36K $517.93K $14.57K ▲ +0.0 pp
2023 100.0% $60.09K $60.09K $74.37K $14.28K ▲ +0.0 pp
2022 100.0% $10.23K $10.23K $10.23K $0.00 —
pp = percentage points